SCHEDULE: LeMaitre Vascular CEO Discloses 7.43% Stake

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, Inc., reported beneficial ownership of 7.43% of the company's common stock as of September 30, 2025.

Summary

• George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, Inc., filed an Amendment No. 19 to Schedule 13G.
• He beneficially owns 1,684,603 shares of LeMaitre Vascular, Inc. Common Stock.
• This represents 7.43% of the total 22,681,504 shares outstanding as of September 30, 2025.
• The ownership includes 1,663,303 shares held directly and 21,300 shares held in a trust for his children, for which he disclaims ownership.

Sentiment

Score: 7

Explanation: The filing indicates a significant beneficial ownership by the CEO, which is generally a positive signal for investor confidence due to strong alignment of interests. No negative information is present.

Positives

• High insider ownership by the Chairman and CEO, George W. LeMaitre, at 7.43% of the company's common stock.
• Significant stake suggests strong alignment of management interests with shareholder interests.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The amount in row 9 includes (i) 1,663,303 shares of Common Stock held of record by George W. LeMaitre, and (ii) 21,300 shares of Common Stock held by a trust for the benefit of Mr. LeMaitre's child(ren) and which securities Mr. LeMaitre disclaims ownership.

Industry Context

This filing is a standard disclosure of insider ownership and does not provide specific industry context or competitive analysis. However, significant insider ownership is generally viewed positively as it aligns management's interests with those of shareholders, a common factor across industries.

Comparison to Industry Standards

• A 7.43% beneficial ownership by a CEO is a substantial stake, often considered a strong indicator of management's confidence in the company's long-term prospects.
• While direct comparisons to specific competitors are not provided in this filing, such a level of insider ownership is generally above average for CEOs of publicly traded companies, particularly in the medical device sector where founders often retain significant stakes.

Stakeholder Impact

• Shareholders: High insider ownership by the CEO can be seen as a positive signal, potentially increasing investor confidence and aligning management's long-term vision with shareholder value.

Next Steps

• This filing does not outline specific future actions or milestones for the company, as it is a disclosure of beneficial ownership.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses the beneficial ownership of George W. LeMaitre, the Chairman and CEO, holding 7.43% of the company's common stock. While significant insider ownership is generally a positive indicator of management's commitment and belief in the company's future, this filing alone does not provide sufficient new financial or operational data to warrant a change in investment recommendation. It confirms a stable and substantial insider stake, which supports a 'hold' position for existing investors, but does not present new catalysts for 'buy' or 'sell' decisions.

Keywords

LeMaitre Vascular, LMAT, George W. LeMaitre, Beneficial Ownership, Insider Ownership, SEC Filing, Schedule 13G, Common Stock, Chairman, CEO